zurück

EU-HTA

#

Key Updates on AMNOG & EU HTA Alignment

13.03.2025
Thrilling news ahead: the previously proposed 3-month suspension of the AMNOG process is not included in the final version of the First Regulation Amending the Ordinance on the Benefit Assessment of Medicinal Products...
#

IQWiG Allgemeine Methoden

11.03.2025
IQWiG just published the draft of their General Methods 8.0 but does not propose separate methods for EU HTA...
#

New PICO Exercises Released: What Can We Learn?

04.03.2025
Lots of PICOs again - 3 of them just for the G-BA?...
#

New PICO Exercises Released: What Can We Learn?

26.02.2025
Lots of PICOs and only one of two PICOs for German AMNOG covered!...
#

New PICO Exercises Released: What Can We Learn?

19.02.2025
Why has publication taken that long?...
#

New PICO Exercises Released: What Can We Learn?

12.02.2025
Exciting news from the Coordination Group: Second wave of PICO exercises published!...
#

Guidance on scoping (G05) published 

17.01.2025
G05 defines the essence of the respective HTA ...
#

Procedural Guidance for JCA (G07) published

16.01.2025
Today we will take a closer look at at the procedures around JCA...
#

Actual Template for JCA (G08) published 

15.01.2025
This is not the official template - but actually it‘s intended to be...
#

Get ready for EU HTA - Provide training

14.01.2025
EU HTA will completly change the process of Market Access in Europe...
#

EU HTA - Here we go

13.01.2025
EU HTA starts from today for new active substances in oncology and ATMPs submitted for MAA...
#

Procedural Guidance for JSC on MPs (G10) published 

08.01.2025
The "primary reference (…) throughout the JSC procedure."...

 

Ansprechpartner

Dr. Thomas Ecker

Dr. Thomas Ecker
Tel. +49 (40) 41 33 081-10

 

Janine Leismann

Janine Leismann
Tel. +49 (40) 41 33 081-26